The behind-the-curtain look at how a clinical research site actually runs. Written for people looking to enter the clinical trial world, for new coordinators learning the ropes, and open to anyone curious what happens at clinical research sites.

In this file:

·        Why the investigational product is tracked more carefully than almost anything else at a site

·        What Lynn, the site pharmacist, actually does behind that locked door

·        The temperature log and the drug count, and why a gap in either becomes everyone's problem

·        What accountability means when it is not your own body on the line

Walter, our invented Study OLS-114 patient, got his first dose in Issue 4. This issue is about the part he never sees: everything that has to be true before a single dose reaches him, and everything that has to be documented after.

Every site running Study OLS-114 has one room, or at minimum one locked, temperature-monitored cabinet, that belongs entirely to the investigational product, the IP. Lynn, the pharmacist, is the only person on the delegation log authorized to receive it, store it, prepare it, and dispense it. Not because anyone doubts the rest of the team, but because the protocol requires a single accountable line, one person who can answer for every unit of drug from the moment it arrives to the moment it is given, returned, or destroyed.

When a shipment arrived for OLS-114, Lynn's first job was not to open it. It was to check the temperature log the shipping container generates automatically during transit. If that log showed even a brief excursion outside the range the protocol allows, the drug does not get used, full stop, until the sponsor confirms in writing that it is still viable. A cold chain is not a suggestion. It is the difference between a drug that behaves the way its data says it should and one that might not.

Once a shipment clears, Lynn logs it into the site's drug accountability record: how many units arrived, the lot number, the expiration date. From there, every single unit is tracked until it leaves the site, whether it goes into a patient, gets returned unused, or gets destroyed per the sponsor's instructions. Dispensed to Walter. Logged. Returned by another patient who missed a dose and brought the bottle back, as instructed. Logged and counted, because unused doses tell the study almost as much as the ones that were taken; it is one of the honesty checks. Every one of those events gets written down the day it happens, never reconstructed later from memory.

This is the same discipline Lynn described to Nani back in Issue 1, when she was still three days into the job: if the temperature log has a gap, or the count is off by one, that is Lynn's to answer for, and the chain only holds if every link does. Nothing about that has changed since Study OLS-114 went live; if anything, it matters more now that there is a real patient depending on it.

Note to File: A single unexplained number in a drug accountability log does not stay a small problem. An auditor who finds one unaccounted-for unit has to ask whether it is a clerical error or something worse, and until that question is answered, every other number in that log is suspect too. The fix is not perfection. Mistakes happen. The fix is documenting the correction the same day, in writing, with a reason, so the record explains itself instead of raising more questions.

When Walter arrived for his dose, Lynn did not simply hand it over. She confirmed his identity, confirmed his randomization number matched the kit she was about to open, confirmed the kit's own expiration date and condition, and only then dispensed it, recording the date, time, lot number, and her own initials in the same motion. Every one of those checks exists because the alternative, dispensing based on familiarity or a quick glance at a chart, is exactly how the wrong dose reaches the wrong person, or how a data point becomes impossible to trust later.

Lynn is not gatekeeping for its own sake. She is the reason that six months from now, when someone reviews every dose Walter ever received, the answer is not "probably" but a documented, countable fact.

Nani asked Lynn, once, whether the constant counting ever felt excessive for a drug that, statistically, was probably going to be fine either way. Lynn's answer was the kind of plain honesty the job runs on: it does not matter what is statistically probable for one patient. It matters that the record can prove, for every patient, exactly what happened. That is not paperwork for its own sake. It is the only thing standing between "we believe this worked" and "we can show this worked."

The investigational product gets tracked more carefully than almost anything else at a site because it has to. A temperature excursion or an unexplained count does not stay a small problem; it puts every other number in the study in question. One person owns that chain of custody, checks identity and dose against the system before anything is dispensed, and documents the same day, every time. That discipline is not distrust of the team. It is what makes the eventual results worth believing.

·        Root to Rx: the newsletter and The Root Room, the patient-facing side of the same story, at roottorx.com

·        Root to Rx: free Patient Logs at shop.roottorx.com, the patient-side habit of writing it down the same day it happens

·        FDA — E6(R3) Good Clinical Practice, Guidance for Industry (adopted by FDA Sept 9, 2025)

·        21 CFR Part 312 — Investigational New Drug Application (eCFR)

·        ICH E6(R3) Good Clinical Practice — Step 4 Final Guideline (Jan 6, 2025)_Step4_FinalGuideline_2025_0106.pdf)

·        ClinicalTrials.gov — NIH/NLM clinical trials registry

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. Study OLS-114, Walter, and all names are invented. Always follow your own site's SOPs, your protocol, and your PI and QA team. Characters are composites.

Filed by Justin Yamashita, MSc., Open Label Media

Next in the file: safety reporting, and the clock that starts the moment an adverse event becomes known.